O-Methyl-AL-34662, also known as indazole-5-MeO-AMT, is a serotonin receptor agonist and putative serotonergic psychedelic of the indazolethylamine family related to the psychedelic tryptamine 5-MeO-AMT. It is an analogue of 5-MeO-AMT in which the indole ring has been replaced with an indazole ring and the active enantiomer has been purified.
The drug is a potent agonist of the serotonin 5-HT<sub>2</sub> receptors, including of the serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub> receptors. It is a partial to full agonist of the serotonin 5-HT<sub>2A</sub> receptor and a full agonist of the serotonin 5-HT<sub>2C</sub> receptor. Both O-methyl-AL-34662 and 5-MeO-AMT showed around 10-fold lower potency as agonists of the serotonin 5-HT<sub>2A</sub> receptor compared to the serotonin 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors. The drug has roughly the same activational potencies and efficacies at the serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub> receptors as 5-MeO-AMT.
It potently induces the head-twitch response, a behavioral proxy of psychedelic effects, in mice, and hence may have hallucinogenic effects in humans. Its effective dose for induction of the head-twitch response was 0.16mg/kg, which was about the same as that of (R)-DOI (0.13mg/kg) and was about 6-fold more potent than 5-MeO-AMT (1.0mg/kg).
O-Methyl-AL-34662 was first described in the scientific literature by Jesse May and colleagues by 2006.
In contrast to the case of O-methyl-AL-34662, the corresponding "flipped" indazole analogue of 5-MeO-DMT has profoundly reduced potency as a serotonin 5-HT<sub>2A</sub> receptor agonist relative to 5-MeO-DMT (~1,250-fold lower activational potency).